Related references
Note: Only part of the references are listed.Clinician-reported outcome measures in lupus trials: a problem worth solving
Kathryn Connelly et al.
LANCET RHEUMATOLOGY (2021)
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2021)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage
Shilpa Arora et al.
ARTHRITIS CARE & RESEARCH (2020)
Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus
Khaled Mahmoud et al.
RHEUMATOLOGY (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index
Kenneth C. Kalunian et al.
RHEUMATOLOGY (2018)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
Jayne Little et al.
RHEUMATOLOGY (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
Measuring lupus arthritis activity using contrasted high-field MRI. Associations with clinical measures of disease activity and novel patterns of disease
Eric S. Zollars et al.
LUPUS SCIENCE & MEDICINE (2018)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Systemic lupus erythematosus
Arvind Kaul et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research
Jamal Mikdashi et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Which outcome measures in SLE clinical trials best reflect medical judgment?
Aikaterini Thanou et al.
LUPUS SCIENCE & MEDICINE (2014)
Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?
Marilyn C. Pike et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Interrater reliability: the kappa statistic
Mary L. McHugh
BIOCHEMIA MEDICA (2012)
Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus
Guillermo J. Pons-Estel et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity
Chee-Seng Yee et al.
RHEUMATOLOGY (2009)
Share Paper
